Targacept anticipates that its Phase I program for TC-6499 will include, in addition to the ongoing single dose trial, a multiple rising dose trial. Under its agreement with
XL019 is an investigational small molecule that selectively inhibits the tyrosine kinase JAK2, one of four JAK family members activated in response to cytokines and hematopoietic growth factors.
As the exclusive marketer and distributor of this product for the store brand over-the-counter market in the US, Perrigo expects to begin shipping its product during the first
The company said that the credit facility is available to provide with additional capital as Third Wave executes its plan for leadership in the human papillomavirus (HPV) and
The convertible senior notes mature in 2037 and will pay interest semiannually at a rate of 2% per annum until December 15, 2013, after which their principal will
The patents cover inhaled insulin treatment for diabetes. Detailed terms of the settlement were not disclosed. The lawsuit was originally filed in August 2006 in US Federal Court
The submission maintains the previously proposed global trial design, with clarifications requested by the FDA. The Phase III trial will continue to be a randomized, double-blinded trial, and
The trial showed that SNS-595 was generally well tolerated with anti-leukemic clinical activity when administered either once- or twice-weekly at biologically active doses to patients with relapsed or
The trial is designed to evaluate the safety and efficacy of TRU-015 in subjects with non-Hodgkin’s lymphoma (NHL). The trial is expected to enroll approximately 120 NHL subjects
In this cohort, nine patients received 350mg of bevirimat solution once daily and two patients received placebo for 14 days on top of their failing background regimen. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.